Osteonecrosis of the jaw in patients with osteoporosis - Bisphosphonate therapy, risk factors, clinical symptomatology, initial intervenstions and recommendations;Osteonekrosedes kiefers bei osteoporosepatienten: Bisphosphonattherapie, risikofaktoren, klinische symptomatik, initiale interventionen und empfehlungen

Osteologie

Volumn 21, Issue 3, 2012, Pages 207-212

  Felsenberg, Dieter ^a   Lopez, S ^a   Gabbert, T ^a   Hoffmeister, B ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Antiresorptive therapy; Bisphosphonates; ONJ register; Osteonecrosis of the jaw; Osteoporosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ARTICLE; GERMANY; HUMAN; JAW OSTEONECROSIS; OSTEOPOROSIS; PREVALENCE; REGISTER; RISK FACTOR; SYMPTOMATOLOGY;

EID: 84867585376     PISSN: 10191291     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1621687     Document Type: Article

References (10)

1. Bock O. Die Wirkung der antiresorptiven Therapie am Knochen. Osteologie 2012; 21: 63-69.
2. Diel I. Kieferosteonekrosen in der Osteoonkologie. Osteologie 2012; 21: 193-200.
3. Ebetino FH, Hogan AM, Sun S et al. The relationship between the chemistry and biological activity of the bisphosphonates. Bone 2011; 49 (1): 20-33.
4. Hadji P. BEST-Studie: Neueste Daten zur Volkskrankheit Osteoporose in Deutschland. Osteologie-Kongress, 29.-31 März 2012, Basel.
5. Jakob F, Seefried L, Ebert R. Pathophysiologie des Knochenstoffwechsels bei Osteonekrosen im Zusammenhang mit starker antiresorptiver Therapie. Osteologie 2012; 21: 186-192.
6. Khosla S, Burr D, Cauley J et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22 (10): 1479-1491. (Pubitemid 351229318)
7. Marx RE. Pamidronate (Aredia®) and zoledronate (Zometa®) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61 (9): 1115-1117. (Pubitemid 37064711)
8. Pazianas M, Cooper C, Ebetino FH, Russell RG. Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag 2010; 6: 325-343.
9. Rizzoli R, Burlet N, Cahall D et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 2008; 42(5): 841-847.
10. http://de.statista.com/statistik/daten/studie/1365/umfrage/ bevoelkerung-deutschlands-nachaltersgruppen/ Dezember 2009